Clinical trial
A Multicenter, Single-arm Study of the Efficacy and Safety of Selinexor Combined With Venetoclax as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome
NCT06765928 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Single-arm Study of the Efficacy and Safety of Selinexor Combined With Venetoclax as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 1, 2025
- Completion date
- January 1, 2028
- Enrollment
- 73 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
aml, adult, mds